or Try an Advanced Search...

    Hepatitis C Virus Infection Stocks List

    Symbol Grade Name % Change
    BMY F Bristol-Myers Squibb Company 2.09
    IONS F Ionis Pharmaceuticals, Inc. 2.79
    RGLS D Regulus Therapeutics Inc. 1.33
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Hepatitis C Hepatitis C Virus Biopharmaceutical Diabetes Dystrophy Genetics Hepatitis B Hepatitis B Virus Lipodystrophy Treatment Of Diabetes Acromegaly Alcohol Alnylam Pharmaceuticals Alport Syndrome Amyloid Amyloidosis Angioedema Antisense RNA Apatorsen Atherosclerosis

    Related ETFs - A few ETFs which own one or more of the above listed Hepatitis C Virus Infection stocks.

    Symbol Grade Name Weight
    FTXH D First Trust Nasdaq Pharmaceuticals ETF 6.53
    MEDX F Horizon Kinetics Medical ETF 4.71
    WBIY C WBI Power Factor High Dividend ETF 4.09
    XPH F SPDR S&P Pharmaceuticals ETF 3.74
    ARKG D ARK Genomic Revolution Multi-Sector ETF 3.65
    View all Hepatitis C Virus Infection ETFs...
    Compare ETFs
    Compare FTXH to MEDX Compare WBIY to ARKG Compare XPH to ARKG

        Hepatitis C Virus Infection Stocks Recent News

        Date Stock Title
        May 31 IONS Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
        May 31 IONS Ionis hereditary angioedema therapy succeeds in late-stage trials
        May 31 IONS Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
        May 31 BMY Bristol Myers Squibb’s Breyanzi gains FDA approval for lymphoma
        May 30 BMY Bristol-Myers Squibb's Options: A Look at What the Big Money is Thinking
        May 30 BMY Bristol Myers' Breyanzi gains additional indication for mantle cell lymphoma
        May 30 BMY Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion
        May 29 BMY Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
        May 29 BMY Bristol-Myers gets EU approval for Opdivo for bladder cancer
        May 29 BMY BMS secures another EC approval for Opdivo combination
        May 29 BMY BMS stakes $80m on Prothena’s neurodegenerative candidate
        May 29 BMY Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
        May 28 IONS Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism
        May 28 BMY ASPIRE: Our Commitment To Address Health Inequities in Low- and Middle-Income Countries
        May 28 IONS Ionis to hold donidalorsen Phase 3 data webcast
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Hepatitis C Hepatitis C Virus Biopharmaceutical Diabetes Dystrophy Genetics Hepatitis B Hepatitis B Virus Lipodystrophy Treatment Of Diabetes Acromegaly Alcohol Alnylam Pharmaceuticals Alport Syndrome Amyloid Amyloidosis Angioedema Antisense RNA Apatorsen Atherosclerosis
        Hepatitis C Virus Infection

        Hepatitis C virus (HCV) infection is a contagious liver disease caused by the hepatitis C virus. It is spread through contact with the blood of an infected person. Symptoms of HCV infection can range from mild to severe and may include fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, clay-colored stools, joint pain, and jaundice. In some cases, HCV infection can lead to serious liver problems, including cirrhosis and liver cancer. Treatment for HCV infection typically involves a combination of antiviral medications.

        Browse All Tags